BA-BCS 2024 PROGRAM

 

TUESDAY, 3 SEPTEMBER

Welcome and Opening Keynote Lecture

15:00-17:00        Registration

17:00-17:30        Welcome from organizers

17:30-18:30        Opening Conference
Chairs:
Gabriel Rabinovich, IBYME-CONICET, Buenos Aires, Argentina and Edith Kordon, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.

Robert Clarke, University of Manchester, Manchester, UK

The role of cytokines in regulating cancer stem cells in therapy-resistance and metastasis

 

WEDNESDAY, 4 SEPTEMBER 

 

9:30-11:00 /  Session 1: Luminal breast cancer
Chairs:
Caroline Lamb, IBYME-CONICET, Buenos Aires, Argentina and María F. Rubio, IDIM-UBA-CONICET, Buenos Aires, Argentina

9:30-10:00          Todd Miller, Medical College of Wisconsin Cancer Center, Milwaukee, USA.

Leveraging endocrine and metabolic vulnerabilities in ER+ breast cancer.

 10:00-10:30        Joseph Jerry, University of Massachusetts, Amherst, USA.

A panel of normal breast epithelial cells from donors differing in breast cancer risk: variation in barriers to immortalization and estrogen signaling.

10:30-10:45      Short communication to be selected from poster presentations

10:45-11:00        Discussion

11:00-11:30      Coffee Break & Poster Session 1

 

11:30-13:00 / Session 2: Luminal breast cancer 2
Chairs:
Natalia Rubinstein, iB3, FCEyN, UBA, Buenos Aires, Argentina and Vanina Medina, BIOMED-CONICET, UCA, Buenos Aires, Argentina

11:30-12:00        Jennifer Richer, University of Colorado, Aurora, USA.

AR action in ER+ breast cancer – preclinical and clinical trial updates

12:00-12:30        Federico Waisberg, Instituto Fleming, Buenos Aires

New treatments and biomarkers in hormone resistant (HR+) breast cancer.

12:30-12:45        Short communication to be selected from poster presentations

12.45-13:00        Discussion

 

13:00-14:30 / Lunch and Poster Session 1

 

14:30-16:30 / Session 3: Biology and treatment of TNBC
Chairs: Vanesa Gottifredi, Instituto Leloir, CONICET, Buenos Aires, Argentina and Maria José Rico, Facultad de Ciencias Médicas, UNR, Rosario, Argentina

14:30-15:00        Violeta Serra, Vall d’Hebron Institut d’Oncologia (VHIO), Barcelona, Spain.

PARP inhibition in breast cancer

15:00-15:30        Paolo Ceppi, University of Southern Denmark, Odense, Denmark.

Propionate suppresses epithelial-to-mesenchymal transition and reduces the aggressiveness of lung carcinoma, can we extrapolate to breast cancer?

15:30-16.00       Pablo Mandó, CEMIC, Buenos Aires

New therapeutic options for TNBC

16:00-16:15  Short communication to be selected from poster presentations.

16:15-16:30        Discussion

 

16:30-18:00 / Poster Session 1

17:30-19.00 / Round Table 1 (Spanish)
Coordinadoras: Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina  y María Roqué, IHEM-CONICET, Mendoza, Argentina

 Utilidad clínica de la búsqueda de marcadores circulantes en biopsia líquida, para el redireccionamiento y/o seguimiento de la carga tumoral en pacientes con cáncer de mama.

 

THURSDAY, 5 SEPTEMBER 

 

9:30-11:15 / Session 4: Cancer Stem Cells and Tumor Initiation
Chairs:
Albana Gattelli, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina and Catalina Lodillinski, Instituto Ángel Roffo, Buenos Aires, Argentina

9:30-10:00           Fariba Behbod, University of Kansas, Kansas City, USA.

Ductal carcinoma in situ: Transcriptional diversity and stemness.

10:00-10:30        Jochen Maurer, University Hospital RWTH, Aachen, Germany.

Cancer stem cells as disease models in research – opportunities and challenges.

10:30-11:00        William Muller, Rosalind and Morris Goodman Cancer Center, Montreal, Canada.

Title to be determined.

11:00-11:15        Discussion

 

11:15-11:45 Coffee Break and Poster Session 2

 

11:45-13:30 / Session 5: Breast Cancer Genomics and Transcriptomics
Chairs: Ignacio Schor, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina and Marianela Candolfi, INBIOMED, FMED, UBA, Buenos Aires, Argentina.

 11:45-12:15        Martin Abba, UNLP, La Plata, Argentina

Old questions, new tools

12:15-12:45        Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York City, USA.

Breast cancer genomics and resistance to CDK4/6i or on MSK Breast Molecular Tumor Board.

12:45-13:00        Gonzalo Gomez Abuin, Hospital Alemán, Buenos Aires

Utility of next generation sequencing in breast cancer

13:00-13:15        Short communication to be selected from poster presentations

13:15-13:30        Discussion

 

13:30-15:00 Lunch and Posters Session 2

 

15:00-17:00/ Session 6: Fighting treatment resistance
Chairs:
Georgina Coló, INIBIBB-UNS, Bahía Blanca, Argentina and Germán A. Gil, CIQUIBIC, UNC-CONICET), Córdoba, Argentina

15:00-15-30        Adrian Lee, University of Pittsburgh, Pittsburgh, USA.

Endocrine resistance in breast cancer metastasis.

15:30-16:00        Dejan Juric, Massachusetts General Hospital, Boston, USA.

Novel PI3Ki inhibitors including mutant-selective PI3K inhibitors

16:00-16:30      María Vivanco, CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.

Breast Cancer Heterogeneity and resistance to hormone therapy

16:30-16:45       Short communication to be selected from poster presentations

16:45-17:00       Discussion

 

17:00-18:00 Coffee Break and Poster Session 2

 

18:00-19.30 / Round Table 2 (Spanish)
Coordinadores: Mario Rossi Universidad Austral, Pilar, Argentina y Pablo Mandó, CEMIC, Buenos Aires, Argentina

Jerarquización en investigación dentro de la carrera de formación de los médicos, experiencias en CEMIC, Fleming y Austral.

 

FRIDAY, 6 SEPTEMBER 

 

9:30-11:15 / Session 7: Early detection and treatment
Chairs: Giselle Peters, Instituto Ángel Roffo, Buenos Aires, Argentina and Leandro E. Mainetti, Facultad de Ciencias Médicas, UNR, Rosario, Argentina

9:30-10:00           Roger Chammas, Center for Translational Research in Oncology, University of São Paulo, Brazil.

miRNAs as biomarkers for early onset Triple Negative Breast Cancers.

10.00-10:30        Cathrine Park, University of California, San Francisco, USA.

Evolution of breast radiotherapy options for today’s early stage patients.

10:30-10:45     Adriana de Siervi, Oncoliq, Buenos Aires.

miRNAs for early cancer detection in liquid biopsy.

10:45-11:00       Short communication to be selected from poster presentations.

11:00-11:15        Discussion

 

11:15-11:45 Coffee Break and free Poster Session 

 

11:45-13:30 / Session 8: Understanding and modeling breast cancer subtypes
Chairs: Paola Rojas, IBYME-CONICET, Buenos Aires, Argentina and María T. Branham, IHEM-CONICET, Mendoza, Argentina

11:45-12:15        Steffi Oestereich, University of Pittsburgh, Pittsburgh, USA.

Invasive lobular breast cancer – what’s different and why is this important?

12:15-12:45        Alana Welm, University of Utah, Salt Lake City, Utah, USA.

Using patient-derived models for drug discovery and functional precision oncology in advanced breast cancer

12:45-13:00    Short communication to be selected from poster presentations.

13:00-13:15       Short communication to be selected from poster presentations.

13:15-13:30        Discussion

 

13:30-15:00 / Lunch and free Poster Session 

 

 15:00-15:45  / Session 9: Improving life quality
Chair: Mario Rossi, Universidad Austral, Pilar, Argentina

15:00-15:30    Syril Pettit, Health and Environmental Sciences Institute (HESI), Washington DC, USA.

Addressing Cancer Therapy Related Adverse Effects – An Opportunity to Improve Quality of Life and Outcome for Patients

15:30-15:45        Discussion

15:45-16:45  / Closing Conference
Chairs: Osvaldo Podhajcer, Instituto Leloir, CONICET, Buenos Aires, Argentina and  Claudia Lanari, IBYME-CONICET, Buenos Aires, Argentina.

Katherine Hoadley, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.

Quantitative Medicine for Breast Cancer Patients

 16:45-17.00 /   Final discussions and closing remarks

Organizers

17:00-18:00 Coffee Break and free Poster Session

18:00:19:30 / Round Table 3 (Spanish)
Coordinadores: Virginia  Novaro, IBYME-CONICET, Buenos Aires, Argentina y Federico Waisberg, Instituto A. Fleming, Buenos Aires, Argentina.

Navegación en el sistema de salud para pacientes con bajo y alto riesgo de cáncer de mama. Situación actual en la región Norte, Centro y Sur del país.